Loss of glucose homeostasis during sepsis is associated with increased organ dysfunction and higher mortality. Novel therapeutic strategies to promote euglycemia in sepsis are needed. We have previously shown that early low-level intravenous (IV) dextrose suppresses pancreatic insulin secretion and induces insulin resistance in septic mice, resulting in profound hyperglycemia and worsened systemic inflammation. In this study, we hypothesized that administration of low-level dextrose via the enteral route would stimulate intestinal incretin hormone production, potentiate insulin secretion in a glucose-dependent manner, and thereby improve glycemic control in the acute phase of sepsis. We administered IV or enteral dextrose to 10-week-old male C57BL/6J mice exposed to bacterial endotoxin and measured incretin hormone release, glucose disposal, and proinflammatory cytokine production. Compared with IV administration, enteral dextrose increased circulating levels of the incretin hormone glucose-dependent insulinotropic peptide (GIP) associated with increased insulin release and insulin sensitivity, improved mean arterial pressure, and Abbreviations: AUCg = area under the glucose curve; DPP IV = dipeptidyl-peptidase IV; FSIVGTT = frequently sampled intravenous glucose tolerance test; GIP = glucose-dependent insulinotropic peptide; GLP-1 = glucagon-like peptide-1; IV = intravenous; LPS = lipopolysaccharide (also referred to as endotoxin); Si = insulin sensitivity
INTRODUCTION
Dysregulation of glucose control complicates approximately 12% of sepsis cases and increases both morbidity and mortality. [1] [2] [3] Glucose homeostasis in critical illness is impacted by inflammation, insulin resistance, stress hormone release, calorie provision (intentional or unintentional), and insulin administration. [4] [5] [6] [7] Although initial clinical trials supported tight glycemic control using exogenous insulin to improve patient outcomes, 8, 9 subsequent trials highlighted a risk of hypoglycemia with this strategy. [10] [11] [12] [13] Thus, a treatment approach that maintains euglycemia in septic patients without increased hypoglycemic risk is needed. To date, such a strategy has presented a therapeutic challenge but is potentially achievable by activation of endogenous metabolic regulatory pathways.
Hyperglycemia in sepsis shares many characteristics with an accelerated form of type 2 diabetes mellitus: insulin resistance, pancreatic insufficiency, and impaired glucose disposal in the setting of systemic inflammation. 4, [14] [15] [16] Treatment of diabetes with exogenous insulin carries a risk of hypoglycemia, 17 similar to insulin therapy in sepsis. New diabetic treatment strategies target incretin hormones, which stimulate endogenous insulin secretion in a glucose-dependent manner thereby minimizing the risk of hypoglycemia. The gut-derived incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) are released in response to enteral nutrients and signal to increase pancreatic insulin secretion. 18 Additionally, from a therapeutic perspective, incretin hormones have pleiotropic effects with the potential to reduce inflammation and to increase insulin sensitivity (Si) of peripheral metabolic organs. [19] [20] [21] [22] [23] We were interested in potential therapeutic benefits of manipulating enteral nutrients to stimulate endogenous incretin hormone production in sepsis, facilitating both calorie provision and appropriate insulin secretion to control hyperglycemia while preventing hypoglycemia. Thus, in this study, we tested the effects of acute low-level enteral dextrose provision on glucose disposal, incretin hormone release, and systemic inflammation in endotoxemic mice.
METHODS
Animal care. All experiments were performed in 10-week-old male C57BL/6J mice (Jackson Laboratory) and were carried out in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. Mice were sacrificed via cervical neck dislocation in accordance with guidelines established by the American Veterinary Medical Association.
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Background
Dysregulation of glucose control during sepsis is associated with increased morbidity and mortality. Therapies targeting tight glycemic control in septic patients have been limited in part by the development of hypoglycemia. Novel treatment strategies that promote glucose homeostasis in sepsis are needed.
Translational Significance
In this study, we demonstrate that early enteral dextrose improves glucose disposal, increases insulin secretion, and attenuates systemic inflammatory responses in endotoxemic mice by increasing the incretin hormone glucose-dependent insulinotropic peptide. Our results suggest that targeting the endogenous incretin hormone axis may provide a novel therapeutic strategy for improving outcomes in patients with sepsis.
Vascular catheterization and gastric cannula placement. Detailed descriptions of catheterization techniques have been published previously. 24 Briefly, femoral arterial catheters (MRE-025; Braintree Scientific, Braintree, MA) were implanted in all mice for the purposes of hemodynamic monitoring, arterial blood sampling, and metabolic testing. Catheters were tunneled subcutaneously through the left upper back and connected to a dual channel swivel (Instech Laboratories Inc., Plymouth Meeting, PA) to allow the mice to move freely throughout the experimental period. Catheter patency was maintained with a continuous infusion (7 µL/h) of sterile heparinized normal saline (20 U/mL; Sagent Pharmaceuticals Inc., Schaumburg, IL).
Mice then received femoral venous catheters or gastric cannulas depending on experimental group. Femoral intravenous (IV) catheters were implanted in a similar fashion to the arterial catheters. Gastric cannulas were fashioned from 60-cm Portex polythene tubing (SmithsMedical, Dublin, OH) and were implanted via laparotomy: the abdominal cavity was opened with a 0.5-1.0-cm ventral midline incision on the right side followed by puncture of the greater curvature of the stomach with a 16-gauge sterile needle. Cannulas were inserted into the gastrostomy site, secured with 6.0 silk sutures, tunneled subcutaneously to the base of the neck, and connected to the swivel. All mice received a single dose of intramuscular penicillin G 12.5 mg (Pfizer, New York, NY) at the time of surgery.
Experimental protocol. In a first set of experiments, the effects of IV vs enteral dextrose infusions on metabolic outcomes were tested in an endotoxemia model. Mice were randomized to receive either a venous catheter or a gastric cannula. Mice were permitted 3 days to recover from surgery. On the day of metabolic testing, mice were randomized to receive either intra-arterial lipopolysaccharide (LPS, 1 mg/kg) or vehicle (100 µL of saline) followed immediately by dextrose or saline infusion at 100 µL/h. Food was removed from cages to control caloric intake. As a result, at the time of metabolic and inflammatory testing, mice receiving dextrose would have received approximately 10% of their daily caloric needs.
Five hours after LPS or vehicle (time 0), 50 µL of blood was collected and processed for analysis of inflammatory cytokines circulating in the plasma, and the frequently sampled intravenous glucose tolerance test (FSIVGTT) was immediately conducted per our previously published protocol. 25 The minimal model was applied to the FSIVGTT glucose and insulin response curves to determine glucose disposal (area under the glucose curve [AUCg]), acute insulin response to glucose, and Si. 26 Primary analysis compared endotoxemic mice receiving IV dextrose with those receiving enteral dextrose.
To examine the effect of continuous dextrose infusion on incretin hormone production, a separate group of mice exposed to LPS (1 mg/kg) were randomized to receive IV or enteral dextrose. After 5 hours, 100 µL of whole blood was collected in syringes rinsed with the protease inhibitor Diprotin A and transferred to Eppendorf tubes containing 10 µL of a preservative solution containing aprotinin (5000 KIU/mL), ethylenediaminetetraacetic acid (1.2 mg/mL), and the specific dipeptidyl-peptidase IV (DPP IV) inhibitor Ile-ProIle (0.1 nmol) as previously described. 27 Blood was centrifuged at 10,000 rpm for 10 minutes, and plasma was frozen in liquid nitrogen for subsequent analysis of circulating GIP and GLP-1.
Based on results from the initial IV vs enteral dextrose experiments, a final set of experiments focused on GIP alone (not GLP-1). First, the therapeutic effect of exogenous GIP infusion was examined in a mouse model of impaired glucose tolerance. All mice in this experiment received femoral arterial and venous catheters followed in 3 days by intra-arterial LPS (1 mg/kg) and infusion of IV dextrose at 100 µL/h. Mice were randomized to receive a concomitant continuous infusion of either (1) GIP [4 pmol/kg/min] or (2) vehicle [0.9% saline] at 100 µL/h. Second, the effect of GIP blockade was tested in endotoxemic mice receiving enteral dextrose. Mice in this experiment received arterial catheters and gastric cannulas, and 3 days after surgery, all mice received LPS (1 mg/kg) followed by enteral infusion of dextrose at 100 µL/h. Mice were randomized to receive either (1) intra-arterial GIP receptor antagonist 3Pro-GIP (25 nmol/ kg) or (2) vehicle at the time of LPS administration. In all GIP experiments, blood was sampled and FSIVGTT was performed 5 hours after LPS as described previously. Group assignments are further detailed in Supplementary Table I .
Materials and biochemical assays. Escherichia coli O55:B5 lipopolysaccharide (Sigma-Aldrich, St. Louis, MO) was dissolved in normal saline (1 mg/mL). Pharmaceutical-grade dextrose solution (0.5 g/mL in sterile water) was purchased (Hospira, Lake Forest, IL) for enteral or IV infusion. Diprotin A was obtained from EMD Millipore (Billerica, MA). Aprotinin (5000 KIU/mL), ethylenediaminetetraacetic acid (1.2 mg/mL), and IlePro-Ile (0.1 nmol) were obtained from Sigma-Aldrich. GIP (Catalog No. H-5645) and 3Pro GIP (Catalog No. 4061955) were obtained from Bachem (Torrance, CA).
Blood glucose was measured using a Prodigy Autocode Glucometer (~1 µL of whole blood; Diagnostic Devices, Charlotte, NC). Plasma insulin was measured using the Crystal Chem Ultra-Sensitive Mouse Insulin EnzymeLinked Immunosorbent Assay Kit (Crystal Chem Inc., Downers Grove, IL), and plasma cytokines were measured using BioRad 23-Plex Mouse Cytokine Multiplex Assay (Bio-Rad Laboratories, Hercules, CA). GIP was quantified by Rat/Mouse Total GIP enzyme-linked immunosorbent assay (EMD Millipore, Billerica, MA), and GLP-1 was measured by the MesoScale Discovery Active GLP-1 (version 2) kit (Rockville, MD). All assays were performed according to manufacturer protocols.
Statistical analyses. Statistical analyses were performed using GraphPad PRISM 6 for Windows (GraphPad Software Inc., La Jolla, CA) and Stata Version 13 (StataCorp LP, College Station, TX) in consultation with the statistical core at the University of Pittsburgh Clinical and Translational Science Institute. Data are presented as mean ± standard error of the mean, unless otherwise indicated. Primary analyses comparing mean metabolic and inflammatory end points between endotoxemic mice receiving IV or enteral dextrose were compared by unpaired two-sample t test or Mann-Whitney U test. Additional analyses comparing metabolic end points in IV and enteral dextrose infused groups to respective saline and vehicle controls were assessed via one-way analysis of variance or Kruskal-Wallis test as appropriate with prespecified post hoc analyses by Dunnett test. For incretin infusion and blocking experiments, differences in metabolic outcomes and cytokine levels were compared by t test or Mann-Whitney U test. Results were considered statistically significant for a P-value < 0.05, which was adjusted in post hoc analyses for multiple comparisons.
RESULTS
Enteral dextrose administration improves glucose disposal in endotoxemic mice. Control mice receiving vehicle and either IV or enteral saline demonstrated normal glucose disposal with blood glucose levels returning to baseline within 20 minutes after an IV dextrose bolus (1 g/kg) (Fig 1, A, open circles) . Consistent with our previous studies, 28 neither IV dextrose infusion nor LPS alone Glucose disposal in endotoxemic mice is worsened with intravenous (IV) dextrose infusion but is preserved with enteral dextrose. Glucose-time curves from the frequently sampled intravenous glucose tolerance test (FSIVGTT) in control mice receiving vehicle and saline infusion by either IV or enteral route demonstrate the expected glucose response during metabolic testing in that blood glucose rises acutely in response to a dextrose bolus (1g/kg) and returns to baseline within 20 minutes (A). The infusion of dextrose instead of saline in the absence of endotoxin results in minor differences in glucose disposal varying by the route of administration but blood glucose levels return to baseline within a similar time frame (B). Mice receiving endotoxin (LPS 1 mg/kg) and saline start with lower blood glucose at baseline, but glucose disposal is similar to control mice (C). Infusion of IV dextrose in endotoxemic mice results in severely impaired glucose disposal characterized by an inability to return to baseline blood glucose levels in FSIVGTT (D, open circles). In contrast, infusion of enteral dextrose preserves glucose tolerance in endotoxemic mice (D, closed circles). LPS, lipopolysaccharide.
induced profound glucose intolerance (Fig 1, B and C , respectively, open circles). In contrast, infusion of IV dextrose in the context of endotoxemia markedly impaired glucose tolerance compared with controls with higher peak glucose during metabolic testing and the inability to return to baseline (Fig 1, D 3 /dL·min in IV saline and vehicle group, P < 0.01, Table I ).
Enteral dextrose infusion was associated with preserved glucose disposal as evidenced by the lower peak glucose level and rapid return to baseline during the FSIVGTT (Fig 1, D, solid circles) . Glucose tolerance was improved in endotoxemic mice receiving enteral dextrose (AUCg 9.80 ± 0.45 mg·10 3 /dL·min, P < 0.01) compared with the IV dextrose group and was nearly identical to control mice receiving enteral saline that had not been exposed to LPS (AUCg 9.37 ± 0.58 mg·10 3 /dL·min, P = 0.91).
Enteral dextrose administration improves insulin secretion
and insulin sensitivity in endotoxemic mice. Insulin secretion (Fig 2, A) and insulin sensitivity (Table I) during FSIVGTT were comparable with previously published controls in mice receiving vehicle and IV saline. 28 Exposure to endotoxin in mice receiving IV saline decreased insulin sensitivity (77% reduction, P < 0.01) but increased insulin secretion (183% increase, P = 0.01); similar responses were noted in endotoxemic mice receiving enteral saline. Endotoxemic mice receiving IV dextrose demonstrated reduced insulin sensitivity (88% decrease, P < 0.01) but insulin secretion was unchanged (P = 0.82). In contrast, compared with an equivalent level of IV dextrose, enteral dextrose infusion in endotoxemic mice increased both insulin sensitivity (266% increase, P < 0.01) and insulin secretion (77% increase, P = 0.02).
Enteral dextrose improves hemodynamics and reduces systemic inflammation in response to endotoxemia. Endotoxin exposure increased circulating proinflammatory cytokines interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) in mice receiving IV saline, enteral saline, and IV dextrose (Fig 3, A-C) compared with saline and vehicle controls. Compared with endotoxemic mice receiving IV dextrose, IL-1β, IL-6, and TNF-α were reduced by 36% (P = 0.02), 65% (P < 0.01), and 39% (P = 0.01), respectively, in mice receiving enteral dextrose.
Similarly, mean arterial pressure decreased 5 hours after LPS administration in mice receiving IV dextrose (88.82 ± 3.42 mm Hg) compared with IV saline and vehicle controls (101.20 ± 2.60 mm Hg, P < 0.01) but was preserved in the setting of enteral dextrose administration (99.57 ± 2.41 mm Hg , Fig 3, D) . 
<0.01
Boldface values were considered statistically significant (P < 0.05).
*Absolute difference represents difference between the value of the minimal model variable in the combined enteral dextrose and endotoxin (lipopolysaccharide [LPS]) group minus the value in the combined intravenous (IV) dextrose and LPS group. † P-value for absolute difference as tested by unpaired two sample t test. ‡ Denotes a difference compared to IV saline and vehicle control group with P < 0.05 § Denotes a difference compared to IV saline and vehicle control group with P < 0.01. Fig 4) , whereas circulating levels of GLP-1, which is released more distally in the intestine, did not differ significantly (P = 0.87).
Exogenous GIP infusion improves glucose tolerance, increases blood pressure, and decreases inflammation in endotoxemic mice receiving IV dextrose. Provision of IV dextrose after LPS administration impaired glucose tolerance (AUCg 29.28 ± 5.13 mg·10 3 /dL*·min, Fig 5, A) ; the addition of exogenous GIP infusion rescued glucose disposal (AUCg 12.70 ± 1.86 mg·10 3 /dL·min, P = 0.02). Moreover, GIP infusion increased insulin secretion nearly threefold (P = 0.004, Table II) without a significant change in insulin sensitivity. Finally, concomitant with improved insulin secretion and glucose disposal, GIP infusion decreased circulating IL-6 by 67% (P < 0.01) and improved mean arterial blood pressure (79.43 ± 2.51 mm Hg vs 92.10 ± 0.97 mm Hg, P < 0.01) in endotoxemic mice receiving IV dextrose (Fig 5, E and F Fig 6, A) and reduced pancreatic insulin secretion in response to glucose during the FSIVGTT (acute insulin response to glucose: 85% decrease, P < 0.01) without significantly altering insulin sensitivity compared with enteral dextrose control mice (Table III) .
Similarly, GIP blockade intensified the systemic proinflammatory response with increases in IL-1β (375%, P < 0.01), IL-6 (344%, P < 0.01), and TNF-α (67%, P = 0.01, Fig 6, C-E) . Finally, blockade of GIP signaling decreased mean arterial blood pressure in endotoxemic Insulin secretion during metabolic testing is increased in endotoxemic mice receiving enteral dextrose compared with intravenous dextrose infusion-control mice receiving vehicle and saline infusion demonstrate an appropriate increase in insulin secretion after dextrose challenge in FSIVGTT. Mice receiving intravenous (IV) saline demonstrate a slightly higher peak of insulin secretion compared with mice receiving enteral saline (A). Insulin secretion does not differ significantly between mice receiving IV dextrose and enteral dextrose (B), but does increase in saline-infused mice challenged with endotoxin (C). Insulin secretion is inappropriately low in endotoxemic mice receiving IV dextrose infusion given the degree of hyperglycemia (D, open circles), but is notably increased in endotoxemic mice receiving enteral dextrose. LPS, lipopolysaccharide.
Fig 3.
Enteral dextrose infusion attenuates the systemic inflammatory response following endotoxin and improves mean arterial blood pressure-endotoxin administration increases circulating levels of the proinflammatory cytokines interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) in mice infused with either saline or intravenous (IV) dextrose (A-C). Infusion of enteral dextrose attenuates the proinflammatory response in endotoxemic mice with reductions in systemic cytokines of 40%-60%. Blood pressure measured 5 hours after lipopolysaccharide and just before FSIVGTT is increased in endotoxemic mice receiving enteral dextrose compared with those receiving IV dextrose (D). [* and ** denote difference in IV saline and vehicle group with P < 0.05 and <0.01, respectively. † and † † denote difference in enteral saline and vehicle group P < 0.05 and <0.01, respectively]. mice receiving enteral dextrose 5 hours after LPS from 94.65 ± 3.45 to 79.73 ± 4.18 mmHg (Fig 6, F , P = 0.02).
DISCUSSION
The dysregulation of glucose homeostasis during sepsis represents a breakdown of the body's endogenous metabolic response and has important implications for patient outcomes. The development of hyperglycemia during an episode of sepsis is associated with increased morbidity and mortality. 1, 3 Furthermore, the development of hypoglycemia in critically ill patients (which may occur when exogenous insulin is used to control hyperglycemia) has also been associated with Infusion of exogenous glucose-dependent insulinotropic peptide (GIP) rescues impaired glucose tolerance and reduces interleukin 6 (IL-6) in endotoxemic mice receiving IV dextrose-GIP infusion improves glucose disposal (A) associated with increases in insulin secretion during metabolic testing (B), decreases in circulating levels of the proinflammatory cytokine IL-6 (E), and improvements in mean arterial pressure measured just before metabolic testing (F). Levels of interleukin 1 beta (IL-β) and tumor necrosis factor alpha (TNF-α) are not significantly changed with GIP infusion (C and D). Abbreviations: GIP 4, glucose-dependent insulinotropic peptide 4; IV, intravenous. All mice in this experiment were challenged with LPS and IV dextrose. Boldface values were considered statistically significant (P < 0.05). *Data represented as median (interquartile range) instead of mean ± standard error.
increased short-and long-term mortality. [29] [30] [31] Maintaining euglycemia in septic patients remains challenging because of the complex balance between the effects of acute illness and inflammation, the disruption of endocrine pathways responsible for glucose disposal, and the intentional and unintentional effects of therapeutic interventions employed during critical illness. To date, strategies to control glucose regulation in critically ill patients have focused on the use of exogenous insulin and have been limited by the unintended development of hypoglycemia. 11, 32 Our study suggests that glucose homeostasis in sepsis may be promoted by enteral dextrose-induced stimulation of endogenous incretin hormones which serve to increase pancreatic insulin secretion and attenuate the systemic inflammatory response.
Fig 6.
Disruption of GIP signaling with 3ProGIP blocks the beneficial effects of enteral dextrose in endotoxemic mice-glucose disposal is markedly worsened by 3ProGIP (A) associated with impairments in insulin release during metabolic testing (B). Furthermore, GIP blockade in endotoxemic mice results in increases in interleukin 1 beta (IL-β), tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6), and decreases in mean arterial pressure at the time of metabolic testing (C-F). Previous work in our laboratory supports the hypothesis that an inability to maintain intact endogenous endocrine function worsens outcomes in mouse models of sepsis. First, we demonstrated that the inability to raise endogenous insulin production in response to hyperglycemia predicts mortality in endotoxemic mice. 33 Subsequently, we demonstrated that the development of stress hyperglycemia in mouse models is induced by two "hits," combining an inflammatory insult with an exogenous caloric source, such as parenteral dextrose, which, when combined, disrupt both pancreatic insulin secretion and peripheral insulin sensitivity. 28 In addition, we demonstrated that the effect of exogenous dextrose on glucose metabolism does not follow a traditional dose-dependent relationship. Rather, previous data suggest that septic mice will either maintain normal glucose disposal or undergo a rapid transition to a state of insulin resistance and relative pancreatic insufficiency resembling an acute and accelerated form of type 2 diabetes mellitus. 34 The current study expands our understanding of metabolic function and dysfunction in sepsis by demonstrating that the metabolic and inflammatory responses to exogenous dextrose vary based on route of delivery. Our results demonstrate that administration of dextrose by the enteral route prevents the dysfunction induced by parenteral dextrose in endotoxemic mice. The data further suggest that glucose homeostasis in sepsis is critically dependent on secretion of the endogenous incretin hormone GIP.
Incretin hormones are secreted by intestinal neuroendocrine cells in response to enteral nutrients and stimulate pancreatic insulin secretion in a glucose-dependent manner. 35 GIP is released by K cells, which reside predominantly in the proximal small intestine, and GLP-1 is released by L cells in the distal ileum and colon. 18 Incretins differ in their actions on the pancreatic alpha cell as endogenous GLP-1 inhibits glucagon release, whereas GIP does not; thus, GIP may be beneficial compared with GLP-1 with respect to hypoglycemia. 35, 36 Furthermore, incretins have also been shown to modulate systemic inflammation both in vitro and in vivo. [19] [20] [21] 37, 38 New classes of antidiabetic medications targeting incretin hormones have emerged recently including the long acting GLP-1 receptor analogs (eg, liraglutide and exenatide) and inhibitors of DPP IV (eg. sitagliptin and linagliptin), the enzyme responsible for incretin degradation. 39 GLP-1-based therapies have been developed initially as diabetic individuals demonstrate decreased endogenous GIP signaling 40 ; however, exogenously infused GIP may still remain active in the setting of type 2 diabetes. 41 Our research highlights a novel role for GIP in the setting of sepsis. Initial clinical trials of exogenous incretin hormones in critically ill populations have not demonstrated improvements in glycemic control but have been complicated by the use of enteral nutrients stimulating endogenous incretin production in the placebo group. Importantly, the trials confirm that the risk of hypoglycemia is low in critically ill patients with incretin-targeted therapies, 42, 43 since incretin hormones promote insulin release in a glucose-dependent manner. As such, incretin hormones represent attractive potential therapeutic targets in critical illness. [44] [45] [46] [47] In our model, continuous enteral dextrose infusion in endotoxemic mice increased GIP secretion, improved glucose disposal, increased insulin secretion, improved mean arterial pressure, and attenuated the systemic inflammatory response over 5 hours compared with continuous IV dextrose. Interestingly, we did not observe an increase in the secretion of GLP-1, possibly because the low level of dextrose infused was unable to stimulate the K cells located in the distal small intestine. Exogenous GIP infusion demonstrated therapeutic benefits in endotoxemic mice receiving IV dextrose (who would otherwise have no endogenous GIP release) with improvements in glucose disposal, insulin secretion, and the proinflammatory response. Importantly, the suppression of insulin release, worsened glucose tolerance, and increased proinflammatory cytokines in mice receiving enteral dextrose but with GIP receptor blockade highlight the critical role glucose-dependent insulinotropic peptide plays in the regulation of glucose metabolism in endotoxemia. Our results suggest that exploitation of the endogenous incretin signaling axis by manipulation of enteral nutrients, perhaps as simple as enteral dextrose, may provide a viable therapeutic strategy for patients with sepsis.
Several considerations should be noted in the interpretation of our study. First, the relationship between incretin hormones and systemic inflammation may be more complex than suggested in our manuscript. Recent studies by Kahles et al. demonstrate that proinflammatory cytokines including IL-6 and IL-1β induce incretin hormone release, and that 3ProGIP, in the absence of enteral dextrose as utilized in our study, decreases proinflammatory cytokines in response to LPS. 48, 49 Notably, in the Kahles et al. study, 3ProGIP does not decrease insulin secretion, suggesting other incretin pathways, including GLP-1, remain active. In our study, enteral dextrose increases endogenous GIP (but not GLP-1), increasing insulin secretion and decreasing proinflammatory cytokines-findings that are abrogated by 3ProGIP. The specific induction of GIP alone by enteral dextrose in our model may explain differences in cytokine and insulin secretion compared with Kahles et al. Furthermore, the intraperitoneal LPS model utilized by Kahles et al. may influence incretin release through a local peritoneal inflammation that would not be present with our model of intra-arterial LPS.
Although endogenous GLP-1 is not increased in our model, given the similarities to GIP, targeting GLP-1 either through endogenous stimulation with enteral nutrients or exogenous GLP-1 agonists (which are already in use for the treatment of diabetes mellitus) may have similar beneficial effects. 50, 51 Indeed, a recent study demonstrated that pretreatment with either exogenous GLP-1 agonists or with inhibitors of DPP IV (which should increase levels of both GIP and GLP-1) improved survival after LPS administration in mice. 52 Moreover, stimulation of both GIP and GLP-1 may have additive beneficial inflammatory and metabolic effects, but has not as yet been studied in critical illness. 53 Of note, the current studies initiated IV and enteral infusions immediately after the proinflammatory insult, allowing us to determine the effects of early dextrose infusion in the midst of the acute inflammatory response-a process that is underway in patients with sepsis when they present to the intensive care unit. Additionally, studies were performed in lean nondiabetic mice, and endogenous incretin responses to enteral nutrients may be blunted in diabetic individuals. Thus, septic diabetics may require exogenous infusions of GIP or GLP-1 to improve glycemic control in a similar manner. Further studies in animal models and human studies are needed to continue addressing the role of the incretin hormone pathway in sepsis.
In conclusion, the benefits of early enteral support in critically ill patients are believed to include maintenance of intestinal integrity and reduction in the risk of bacterial translocation during acute illness. [54] [55] [56] Our data suggest that an additional potentially important effect of early enteral nutrition (at trophic levels) may include the activation of incretin hormones, particularly GIP, which promotes euglycemia and modulates the systemic inflammatory response. Further research, including welldesigned clinical trials, will be important for establishing a role for targeting the incretin hormone axis in critical illness.
